Cargando…

A Novel Serum Metabolomics-Based Diagnostic Approach for Colorectal Cancer

BACKGROUND: To improve the quality of life of colorectal cancer patients, it is important to establish new screening methods for early diagnosis of colorectal cancer. METHODOLOGY/PRINCIPAL FINDINGS: We performed serum metabolome analysis using gas-chromatography/mass-spectrometry (GC/MS). First, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishiumi, Shin, Kobayashi, Takashi, Ikeda, Atsuki, Yoshie, Tomoo, Kibi, Megumi, Izumi, Yoshihiro, Okuno, Tatsuya, Hayashi, Nobuhide, Kawano, Seiji, Takenawa, Tadaomi, Azuma, Takeshi, Yoshida, Masaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394708/
https://www.ncbi.nlm.nih.gov/pubmed/22792336
http://dx.doi.org/10.1371/journal.pone.0040459
_version_ 1782237881184550912
author Nishiumi, Shin
Kobayashi, Takashi
Ikeda, Atsuki
Yoshie, Tomoo
Kibi, Megumi
Izumi, Yoshihiro
Okuno, Tatsuya
Hayashi, Nobuhide
Kawano, Seiji
Takenawa, Tadaomi
Azuma, Takeshi
Yoshida, Masaru
author_facet Nishiumi, Shin
Kobayashi, Takashi
Ikeda, Atsuki
Yoshie, Tomoo
Kibi, Megumi
Izumi, Yoshihiro
Okuno, Tatsuya
Hayashi, Nobuhide
Kawano, Seiji
Takenawa, Tadaomi
Azuma, Takeshi
Yoshida, Masaru
author_sort Nishiumi, Shin
collection PubMed
description BACKGROUND: To improve the quality of life of colorectal cancer patients, it is important to establish new screening methods for early diagnosis of colorectal cancer. METHODOLOGY/PRINCIPAL FINDINGS: We performed serum metabolome analysis using gas-chromatography/mass-spectrometry (GC/MS). First, the accuracy of our GC/MS-based serum metabolomic analytical method was evaluated by calculating the RSD% values of serum levels of various metabolites. Second, the intra-day (morning, daytime, and night) and inter-day (among 3 days) variances of serum metabolite levels were examined. Then, serum metabolite levels were compared between colorectal cancer patients (N = 60; N = 12 for each stage from 0 to 4) and age- and sex-matched healthy volunteers (N = 60) as a training set. The metabolites whose levels displayed significant changes were subjected to multiple logistic regression analysis using the stepwise variable selection method, and a colorectal cancer prediction model was established. The prediction model was composed of 2-hydroxybutyrate, aspartic acid, kynurenine, and cystamine, and its AUC, sensitivity, specificity, and accuracy were 0.9097, 85.0%, 85.0%, and 85.0%, respectively, according to the training set data. In contrast, the sensitivity, specificity, and accuracy of CEA were 35.0%, 96.7%, and 65.8%, respectively, and those of CA19-9 were 16.7%, 100%, and 58.3%, respectively. The validity of the prediction model was confirmed using colorectal cancer patients (N = 59) and healthy volunteers (N = 63) as a validation set. At the validation set, the sensitivity, specificity, and accuracy of the prediction model were 83.1%, 81.0%, and 82.0%, respectively, and these values were almost the same as those obtained with the training set. In addition, the model displayed high sensitivity for detecting stage 0–2 colorectal cancer (82.8%). CONCLUSIONS/SIGNIFICANCE: Our prediction model established via GC/MS-based serum metabolomic analysis is valuable for early detection of colorectal cancer and has the potential to become a novel screening test for colorectal cancer.
format Online
Article
Text
id pubmed-3394708
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33947082012-07-12 A Novel Serum Metabolomics-Based Diagnostic Approach for Colorectal Cancer Nishiumi, Shin Kobayashi, Takashi Ikeda, Atsuki Yoshie, Tomoo Kibi, Megumi Izumi, Yoshihiro Okuno, Tatsuya Hayashi, Nobuhide Kawano, Seiji Takenawa, Tadaomi Azuma, Takeshi Yoshida, Masaru PLoS One Research Article BACKGROUND: To improve the quality of life of colorectal cancer patients, it is important to establish new screening methods for early diagnosis of colorectal cancer. METHODOLOGY/PRINCIPAL FINDINGS: We performed serum metabolome analysis using gas-chromatography/mass-spectrometry (GC/MS). First, the accuracy of our GC/MS-based serum metabolomic analytical method was evaluated by calculating the RSD% values of serum levels of various metabolites. Second, the intra-day (morning, daytime, and night) and inter-day (among 3 days) variances of serum metabolite levels were examined. Then, serum metabolite levels were compared between colorectal cancer patients (N = 60; N = 12 for each stage from 0 to 4) and age- and sex-matched healthy volunteers (N = 60) as a training set. The metabolites whose levels displayed significant changes were subjected to multiple logistic regression analysis using the stepwise variable selection method, and a colorectal cancer prediction model was established. The prediction model was composed of 2-hydroxybutyrate, aspartic acid, kynurenine, and cystamine, and its AUC, sensitivity, specificity, and accuracy were 0.9097, 85.0%, 85.0%, and 85.0%, respectively, according to the training set data. In contrast, the sensitivity, specificity, and accuracy of CEA were 35.0%, 96.7%, and 65.8%, respectively, and those of CA19-9 were 16.7%, 100%, and 58.3%, respectively. The validity of the prediction model was confirmed using colorectal cancer patients (N = 59) and healthy volunteers (N = 63) as a validation set. At the validation set, the sensitivity, specificity, and accuracy of the prediction model were 83.1%, 81.0%, and 82.0%, respectively, and these values were almost the same as those obtained with the training set. In addition, the model displayed high sensitivity for detecting stage 0–2 colorectal cancer (82.8%). CONCLUSIONS/SIGNIFICANCE: Our prediction model established via GC/MS-based serum metabolomic analysis is valuable for early detection of colorectal cancer and has the potential to become a novel screening test for colorectal cancer. Public Library of Science 2012-07-11 /pmc/articles/PMC3394708/ /pubmed/22792336 http://dx.doi.org/10.1371/journal.pone.0040459 Text en Nishiumi et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Nishiumi, Shin
Kobayashi, Takashi
Ikeda, Atsuki
Yoshie, Tomoo
Kibi, Megumi
Izumi, Yoshihiro
Okuno, Tatsuya
Hayashi, Nobuhide
Kawano, Seiji
Takenawa, Tadaomi
Azuma, Takeshi
Yoshida, Masaru
A Novel Serum Metabolomics-Based Diagnostic Approach for Colorectal Cancer
title A Novel Serum Metabolomics-Based Diagnostic Approach for Colorectal Cancer
title_full A Novel Serum Metabolomics-Based Diagnostic Approach for Colorectal Cancer
title_fullStr A Novel Serum Metabolomics-Based Diagnostic Approach for Colorectal Cancer
title_full_unstemmed A Novel Serum Metabolomics-Based Diagnostic Approach for Colorectal Cancer
title_short A Novel Serum Metabolomics-Based Diagnostic Approach for Colorectal Cancer
title_sort novel serum metabolomics-based diagnostic approach for colorectal cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394708/
https://www.ncbi.nlm.nih.gov/pubmed/22792336
http://dx.doi.org/10.1371/journal.pone.0040459
work_keys_str_mv AT nishiumishin anovelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT kobayashitakashi anovelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT ikedaatsuki anovelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT yoshietomoo anovelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT kibimegumi anovelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT izumiyoshihiro anovelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT okunotatsuya anovelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT hayashinobuhide anovelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT kawanoseiji anovelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT takenawatadaomi anovelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT azumatakeshi anovelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT yoshidamasaru anovelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT nishiumishin novelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT kobayashitakashi novelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT ikedaatsuki novelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT yoshietomoo novelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT kibimegumi novelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT izumiyoshihiro novelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT okunotatsuya novelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT hayashinobuhide novelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT kawanoseiji novelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT takenawatadaomi novelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT azumatakeshi novelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer
AT yoshidamasaru novelserummetabolomicsbaseddiagnosticapproachforcolorectalcancer